Administration of the P2X7 receptor antagonist BBG reduced tumour volume versus that in controls (intravenous administration; effect depending on the site of injection), as well as reduced migration of glioma cells and expression of this receptor induced by BzATP; however, BBG did not pose any influence on angiogenesis [69]. The gene discussed is P2RX7; the disease is glioma.